Department of Surgery, University Hospital "Tzaritza Joanna - ISUL", Medical University of Sofia, Sofia, Bulgaria
Department of Pathology, Medical University of Sofia, Sofia, Bulgaria.
Anticancer Res. 2019 Aug;39(8):4393-4398. doi: 10.21873/anticanres.13609.
BACKGROUND/AIM: Metastatic breast cancer (MBC) represents a wide spectrum of heterogeneous conditions with different secondary spread sites, time to relapse and biology. MBC is still considered an incurable disease despite the fact that survival rates have improved in the last years. Cutaneous metastases are a rare site for metastatic spread and indicate advanced disease. The aim of this study is to demonstrate the excellent therapeutic result following endocrine therapy only in MBC with just skin involvement.
We present a case of an 82-year-old woman with no family history of breast cancer (BC), who was diagnosed with de novo metastatic estrogen/progesterone receptor-positive and HER2-negative invasive lobular BC. The only site of secondary spread was the skin. She was treated with just endocrine therapy for 116 months with which she achieved and maintained long-term complete clinical response (CR).
To our knowledge this is the only case of lobular BC with de novo metastatic manifestation as multiple skin metastases, which achieved CR following the aromatase inhibitor treatment (anastrozole) with such impressive long-term overall survival.
背景/目的：转移性乳腺癌（MBC）代表了具有不同继发转移部位、复发时间和生物学特征的广泛异质性疾病。尽管近年来生存率有所提高，但 MBC 仍被认为是一种无法治愈的疾病。皮肤转移是转移扩散的罕见部位，表明疾病已进入晚期。本研究旨在展示仅针对皮肤受累的 MBC 进行内分泌治疗后取得的极佳治疗效果。
我们报告了一例 82 岁女性病例，无乳腺癌（BC）家族史，被诊断为新发转移性雌激素/孕激素受体阳性且 HER2 阴性浸润性小叶 BC。唯一的继发转移部位是皮肤。她仅接受内分泌治疗 116 个月，达到并维持了长期完全临床缓解（CR）。
据我们所知，这是首例作为多发皮肤转移的小叶 BC 病例，在接受芳香酶抑制剂（阿那曲唑）治疗后达到 CR，并取得了如此令人瞩目的长期总生存。
